Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00808288 | A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients. | PHASE2 | COMPLETED | 405 | — | — | Mar 1, 2010 | Dec 1, 2010 | Feb 6, 2019 | 75 | United States, Argentina +10 |
| NCT00783406 | Safety, Toleration and Efficacy of Single Inhaled Doses of PF-00610355 in Chronic Obstructive Pulmonary (COPD) Patients. | PHASE2 | COMPLETED | 20 | — | — | Oct 1, 2008 | Mar 1, 2009 | Nov 1, 2010 | 2 | Germany |
| Arm | Type | Description |
|---|---|---|
| PF-00610355 | EXPERIMENTAL | - |
| PF- 00610355 | EXPERIMENTAL | - |
| PF - 00610355 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Salmeterol | ACTIVE_COMPARATOR | - |
| PF -00610355 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PF-00610355 | DRUG | oral, inhaled, dry powder, 600ug, OD |
| PF - 00610355 | DRUG | oral, inhaled, dry powder, 300ug, OD |
| PF- 00610355 | DRUG | oral, inhaled, dry powder, 100ug, OD |
| Placebo | DRUG | oral, inhaled, dry powder, placebo, OD |
| Salmeterol | DRUG | salmeterol, 50ug, BID |
Inclusion Criteria: * Post-bronchodilator FEV1/FVC ratio \<0.7 and a post-bronchodilator FEV1 of 50-80%. * Diagnosis of moderate COPD for a minimum of 6 months. * Stable disease for at least 1 month prior to screening Exclusion Criteria: * More than 2 exacerbations of COPD requiring treatment wit...